Philip Morris International Inc. (PM) Earnings Call Transcript & Summary

July 20, 2023

New York Stock Exchange US Consumer Staples Tobacco earnings 69 min

Earnings Call Speaker Segments

James Bushnell

executive
#1

Good day, everyone, and thanks for being here. We put out a press release earlier today with full details about how we performed in the second quarter of 2023. You can find that release on our site, www.pmi.com. For definitions of terms, including what we mean by smoke-free products, plus adjustments, other calculations, and reconciliations of the non-GAAP financial measures mentioned in this presentation to the closest comparable US GAAP measures, along with extra net revenue data, please see Exhibit 99.2 of the company's Form 8-K dated July 20, 2023, and our Investor Relations website. When we give growth rates on an organic basis, they reflect adjusted results at constant currency, leaving out acquisitions and disposals. That means organic figures and comparisons leave Swedish Match out through November 11, 2023. Remarks today include forward-looking statements and projections about future results. Please see the Forward-Looking and Cautionary Statements disclosure in today's presentation and press release, which reviews the various factors that could make actual results differ materially from projections or forward-looking statements. I'm now happy to hand things over to Emmanuel Babeau, our Chief Financial Officer. The floor is yours, Emmanuel.

Emmanuel Babeau

executive
#2

James, thank you, and good morning, everyone. In the second quarter of 2023, we posted outstanding results that beat what we had projected, setting a quarterly record for adjusted diluted EPS at $1.60. Driving that were formidable momentum behind ZYN and IQOS, along with a sturdy showing in combustibles. We achieved a 3.3% increase in total cigarette and HTU shipment volume, which keeps us firmly on pace for a third straight year of volume growth. That performance made possible double-digit growth in organic topline, plus currency-neutral adjusted diluted EPS growth in the high teens; we also widened our lead in smoke-free products during the quarter. To begin with, IQOS maintained its remarkable forward trajectory. Adjusted in-market sales volumes for the brand rose 16%, while shipments climbed 27%. That signals healthy user growth — 1.4 million additional users joined in the quarter — and continued robust demand worldwide. An expanding portion of this stems from IQOS ILUMA, which is now available in 23 markets and accounts for roughly two thirds of our IQOS business by volume. Then, with two complete quarters now behind us since the Swedish Match acquisition, ZYN is bringing extraordinary momentum to our smoke-free segment. US volumes surged by more than 50%, with a distinct acceleration in June, and we are delighted with how it is doing. Our combustible segment also outperformed our expectations. Organic net revenue there climbed by more than 7%, following a particularly strong quarter on pricing and volumes that proved resilient. That contributed significantly to pushing organic operating income up by over 7%, while our adjusted operating income margin improved sequentially by 210 basis points. Now to the headline numbers: volumes turned in positive, driving very strong organic topline growth of 10.5%, as IQOS sustained its excellent momentum and combustible pricing accelerated further. Those figures exclude Swedish Match's standout pro forma ex-currency topline growth of 19%, which was fueled by ZYN, and combined, pro forma ex-currency net revenues rose 11.1%. In total, our reported currency-neutral net revenues increased 19%. On an organic basis, net revenue per unit sold grew 7.0%, with the gain coming from a greater proportion of IQOS HTUs in our sales mix as well as from combustible pricing. Owing to those favorable dynamics, adjusted operating income on an organic basis rose a very robust 7% even as inflationary pressures continued. That number excludes the enormous growth of ZYN, and starting in Q4, Swedish Match will be incorporated into our organic results. Sequentially, adjusted OI margins were up 210 basis points, and though organically they remain 140 basis points below a year ago, this better-than-expected result drew considerable support from combustible performance and the favorable timing of certain costs. On top of that, we boosted our ownership position in Indonesia’s below Tier 1 segment, which today accounts for roughly 40% of volumes in that market and drags on our margins somewhat. This organic result—combined with favorable cost timing, exceptional June ZYN volumes, and a lower tax rate—let us come in ahead of our most recent Q2 forecast. Adjusted diluted EPS reached $1.60, up 16.9%, excluding a $0.13 currency headwind, mostly from the Japanese yen. While Q1 contained some unusual headwinds and distortions from timing and comparison effects, our business delivered a robust first half, with volumes rising 1.1%. Organic net revenues grew 6.8%, and in H1 Swedish Match posted excellent pro forma net revenue growth of 17% on an ex-currency basis, showing just how much growth it contributes to our business. Taken together on a pro forma, currency-neutral basis, net revenues rose about 7.5%. After the worst margin pressures and a significant operating income decline in Q1, the big Q2 rebound cut the first-half organic decline to minus 2%. As with Q2, Swedish Match isn’t included here; it produced a superb profit result and contributed heavily to our adjusted OI margins, and we expect reported and organic operating income to continue growing strongly in the second half. Despite those challenges, currency-neutral adjusted diluted EPS climbed 5.9% to $2.98 in H1, giving us a solid base for the rest of 2023 and beyond. Now I’ll walk through how Q2 net revenues came together. Swedish Match’s smoke-free volumes rose 15%, and while that number falls outside our reported shipment volume increase of 3.3%, it adds considerable momentum to our overall growth. Pricing for combustibles and HTUs contributed 6 points of growth, mainly from combustible performance, which benefited partly from timing. As in Q1, our heated tobacco unit pricing was hurt in Japan and Germany. That stemmed from the anniversary effect of 2022 excise tax increases, plus Japan’s move to ILUMA. Once those anniversary effects pass, the second half should see less drag from these items. On the German tax surcharge court case, we still expect a clearer read on how it’s likely to resolve near the end of the year. Heated tobacco units represented a larger share of our business again, which helped because we earn more net revenue per unit—though an unfavorable geographic mix partly offset that. The favorable HTU mix, together with volume growth across the board and pricing, are powerful drivers behind our transformation and growth. Now let’s turn to gross margins. Although we were still down versus the same period a year ago, the picture improved relative to Q1, helped by solid underlying growth. Even with inflation climbing, we actually saw a sequential improvement of 1.2 percentage points, because revenue growth accelerated and the strain from supply chain issues along with ILUMA-related items started to lessen over the quarter. Beyond that, the way costs landed and inventory shifted across geographies—particularly for HTUs in Europe—went back toward typical patterns after a Q1 that took a heavy hit. IQOS contributed favorably to gross margin in Q2, and we expect that to persist, helping to counter some of the pressure from combustibles. Turning to H2, we expect the gross margin's year-over-year trajectory to keep getting better as those difficulties continue to diminish, ZYN continues its outstanding growth, and the underlying drivers of our transformation accelerate. During Q2, SG&A expenses increased at a rate much closer to net revenues, which matched what we'd expected, and the pace of that growth appears more consistent with our full-year expectations. Given how strongly the top line did in Q2, those SG&A costs ended up representing a reduced portion of net revenues. Since we keep putting money behind IQOS and ZYN, the efficiency programs that have worked well for us keep producing returns, and those funds help finance our growth investments while also offsetting inflation, which is still a burden. So far, gross savings total $1.9 billion, including $820 million from SG&A, and we now expect to hit our $2 billion target for 2021 to 23 sooner than planned. Moving to the 2023 outlook, we're raising our guidance for currency-neutral growth on both the top and bottom lines. Our ambition is to be a growth company, starting with volumes. For 2023, we expect total volumes to rise for a third straight year, and that's without even factoring in the remarkable strides from Swedish Match's portfolio. Within that growth, we're restating our HTU shipment target of $125 billion to $132 billion—landing in the range of 125 billion to 130 billion on the lower end—and we project cigarette volumes will decline between 1.5% and 2.5%. Our organic net revenue growth outlook is now raised to 7.5% to 8.5%, which captures IQOS's continued momentum, the resilience of our combustible business, and ZYN's ongoing standout results, all of which ought to deliver a positive contribution in Q4.

Emmanuel Babeau

executive
#3

Looking ahead to the remaining months, we expect strong growth in organic operating income, which should drive margin improvement in the second half, despite the challenges we mentioned before and certain technical factors. Those factors come from increased use of contract manufacturers in a few markets, such as Indonesia and Ukraine, along with growth in the below Tier 1 segment in Indonesia that I mentioned earlier. All together, we estimate these items will reduce our adjusted OI margin by about 40 basis points for the entire year, and without that impact, we would expect to finish right around the midpoint of our projected organic margin range. On top of these organic changes, we expect Swedish Match to add roughly 50 basis points of accretion. Thanks to strong results at the top line and in operating income, we can now raise our forecast for adjusted diluted EPS growth on a currency-neutral basis to a range of 8% to 9.5%. In dollar terms, that works out to a new range of $6.13 to $6.22. Within that figure, $0.33 comes from unfavorable currency effects at current exchange rates, driven mainly by the Japanese yen and the Russian ruble. Our outlook continues to assume about $150 million of incremental investments in the US, as well as in our Wellness and Healthcare business. It also assumes net finance costs of roughly $1.2 billion, reflecting higher interest on variable debt that is partly offset by better returns on cash deposits. As we mentioned earlier, we have not included in our projections any upside from a potentially favorable outcome on the Germany tax surcharge. Looking more closely at the back half of the year, we expect solid results on every major measure as smoke-free offerings contribute more and more favorably. For Q3, our forecast is high single-digit growth on an organic topline basis, HTU shipment volumes ranging from 31 billion to 33 billion units, and adjusted diluted EPS between $1.60 and $1.65 — a figure that reflects $0.06 of currency headwinds at prevailing rates. As we move into Q4, we look for reported and organic OI growth to be especially pronounced, since some inflation-related effects will have lapped, and because an improved ILUMA supply chain and consumables keep delivering greater benefits. Swedish Match, as I mentioned, will likewise be included in our organic numbers for that quarter. ZYN's remarkable expansion is obviously helping our margins, which our adjusted H1 numbers make clear. Turning back to the results, Q2 total shipments grew 3.3%, while year-to-date they were up 1.1%. In Q2, HTU shipment volumes reached 31.4 billion units, an increase of 26.6%, mainly because of continued strong momentum in Europe and Japan. Beyond that underlying strength, HTU shipments into Japan received an additional lift of about 2 billion units during Q2 as we increased sea freight, with inventory levels rising in tandem. Total PMI adjusted in-market sales volumes for HTUs, as I mentioned before, were up 16% in Q2, continuing the superb trend we saw in Q1. For H1, shipment volumes were 18.5% higher. What's key here is that this doesn't take into account the strong potential we see in oral nicotine, where pro forma shipment volumes were up 14% in Q2 and 12% in H1. Cigarette volumes dipped a bit in the second quarter — 0.4% — with Turkey and Egypt standing out as notable contributors, and over the first half they were down 1.7%, which reflects a solid category share performance in a resilient category even as pricing went up. Our smoke-free transformation continues to move ahead at a fast pace. With IQOS still delivering impressive results, heated tobacco units accounted for 16.4% of total shipment volume in H1, compared with 14% in the first half of 2022, despite a resilient cigarette category. Adding oral smoke-free products into the mix would bring that number to close to 18%. During the first half, smoke-free offerings made up 35% of adjusted net revenues, with IQOS and ZYN serving as the key drivers — that compares to 30.9% during the same stretch of 2022. IQOS devices contributed approximately 4.5% of inhalable smoke-free net revenues in H1. Now looking at combustibles: our portfolio delivered robust organic net revenue growth, reaching 7.4% in Q2 and 5.2% across H1. This was fueled by particularly strong Q2 pricing, with Indonesia and the Philippines standing out as significant contributors. The unusually high 9.4% Q2 pricing, which got a boost from timing-related factors, isn't something we anticipate will carry through fully into H2, but our updated forecast for the full year is now a 7% to 8% increase. During Q2, our portion of the cigarette market climbed 0.7 points compared with the same period last year, helped by gains in Duty Free, Egypt, and Turkey. Across the first half, that share increased by 0.1 point, which meant volume decreases stayed fairly small. Because we hold a leading position in combustibles, we are better able to move consumers toward smoke-free options, and over the past 18 months we have completely met our continuing goal of keeping category share steady, even with IQOS pulling some volume away. With combustibles share holding firm and our top smoke-free brands still expanding, we are set up to grow total market share as time goes on. In Q2 we gained 1.1 points of share in international cigarettes and HTUs, and 0.5 points in H1, with Turkey and Japan standing out as key contributors. Even with tougher rivalry cropping up across numerous geographies, our share of volume within the expanding heat-not-burn segment holds steady near 75%. Driving this are continued ILUMA rollouts into new markets plus a sharper emphasis on our two-tier HTU lineup, which gives adult smokers a widening selection of inventive, premium-quality cigarette substitutes. Once more, PMI HTUs cemented their standing as the number two nicotine brand wherever IQOS is sold, notching a quarter-over-quarter improvement of 0.2 points in Q2, reaching an all-time high of 9.2% share. As of June 30th, we figure there were 27.2 million IQOS users. We saw great momentum in Q2, adding 1.4 million adult users, and Japan and Europe stood out, along with many other markets. Fundamentals are still quite solid, but I want to flag that Q3 user growth frequently comes in under the yearly average because of seasonal patterns we've seen in earlier years. Now let's look at IQOS in the Europe Region, where we're getting close to 12 million users. That figure reflects our push to bring ILUMA to more people, and right now about 70% of IQOS users in that region are able to access it, while the portfolio continues to expand under a two-tier structure. To give a sense of how far it has come, in Spain and Switzerland — the first markets where we launched — TEREA now accounts for nearly 100% of our HTU in-market sales volumes. For the second quarter, our HTU share came in at 9.0% of total cigarette and HTU industry volume, up 1.6 points versus a year earlier. Sequential share, as it typically does, looks distorted by cigarette category seasonality, yet adjusted in-market sales volumes keep showing solid growth quarter over quarter and hit an all-time peak on a four-quarter moving average. This was driven by a robust 20% increase compared with the same period last year during Q2, which exceeded the 11% improvement in HTU shipments that experienced some ongoing effects from the inventory situation observed in Q1. Looking ahead to the second half, we expect meaningful growth in HTU shipments, adjusted in-market sales, and organic net revenues for the region as a whole; we continue to be encouraged by the growing number of European nations implementing multi-year excise tax frameworks, where smoke-free products are unmistakably given separate treatment. At this stage, over 50% of EU member states have adopted multi-year plans. Over in the European Union, a number of member states are also working to bring the Delegated Directive into their own national laws — a step that would end the exemption letting heated tobacco products sidestep the flavor ban.

Emmanuel Babeau

executive
#4

The prohibition is set to take effect on October 23rd, and we'll be making adjustments to our HTU portfolio as needed to comply with this transposition. Although there could be some short-term ups and downs, we don't anticipate any major shift in the category's structural growth. To provide a bit more detail on our ongoing advancements in the area, this slide presents a sample of the most recent key city offtake shares. IQOS keeps succeeding across a wide variety of locations, from Western, Southern, Central, and Eastern Europe, spanning markets both with and without ILUMA. Even with the denominator impacts from the combustible category that I mentioned earlier, the share outcomes are still quite robust. We're really happy with what's happening in Rome, where there's been a sequential increase to 28% share after the ILUMA launch. Strong gains in London and Munich are also encouraging signs for these two important markets. Although the Q2 2022 comparison for share in Vilnius got a boost from the appeal of certain bundle offers, a share above 40% is still remarkable, and underlying offtake keeps expanding; over in Japan, IQOS ILUMA is maintaining its impressive growth trajectory. In H1, smoke-free products accounted for more than 75% of our Japan net revenues, which clearly illustrates the direction for the wider company. Our HTU brands' adjusted total tobacco share rose by 3.4 points in Q2 to 26.3%, further solidifying TEREA and SENTIA as the unmistakable number one and two heat-not-burn brands, even with tougher price competition for mid and low-price options. Crucially, adjusted in-market sales volumes once more increased sequentially, hitting a record 9.3 billion units on a four-quarter moving average, as IQOS surpassed the heat-not-burn category's growth. Alongside this fantastic consumer momentum, our Q2 shipments to Japan also gained from a gradual return to sea freight throughout the quarter; beyond the strong IQOS advances in developed nations, we're still witnessing highly encouraging expansion in low and middle-income markets. This slide showcases a sample of Q2 key city offtake shares from markets in Eastern Europe, Africa, Asia, and Latin America. Some ongoing notable wins are Egypt, where Cairo's offtake share went past 8.5%, and Bulgaria, where Sofia's offtake share topped 15%, even with the typical seasonal effects I brought up. We're still observing solid offtake volume increases in these key future markets. Turning now to Swedish Match, which is significantly speeding up our smoke-free growth path. As discussed before, the business achieved remarkable currency-neutral net revenue growth of 19% in Q2 and 17% in H1. That means during the first half of the year, Swedish Match contributed 70 basis points of currency-neutral growth to our pro forma topline, plus 60 basis points to our adjusted OI margin; in the US, ZYN had another outstanding quarter, with volumes up over 50%, indicating positive momentum nationwide. In other smoke-free areas, the recent patterns of share gains in US moist snuff, along with category mix challenges in Scandinavia, largely persisted. The cigar business did well, posting Q2 organic net revenue growth of 16%. That shows we keep taking share even though we were early to move on pricing in the category. Once more, I want to congratulate and thank every Swedish Match employee for delivering such outstanding results while we carefully bring our operations together, which is going extremely well. Taking a closer look at how ZYN performed in the US, can volumes rose an exceptional 53% year over year, and that also represents a 22% increase from Q1, 2023 on a sequential basis; this faster growth comes from steady gains in distribution and a wide nationwide lift in store velocities, as adult nicotine users embrace the category for its convenience and enjoyable experience. That includes California, where a statewide flavor ban took effect in December. Although growth rates this high might not last forever, the structural signals stay highly encouraging. Notably, ZYN’s category volume share climbed 2.2 points versus the prior year and 1 point sequentially, even with ongoing discounting from less premium offerings. Retail value share also rose to 76.8%, underscoring its premium positioning and stronger brand equity. Now let me give an update on our innovation and expansion plans as we push further ahead with our smoke-free transformation. Above all, the worldwide roll-out of IQOS ILUMA remains a leading priority; we brought ILUMA to six markets during Q2, and since HTU manufacturing constraints have now normalized, we intend to be in roughly 50 markets by year-end. The biggest chance to drive faster growth lies in the US. We are putting investment behind ZYN and getting our organizational and commercial capabilities ready for the IQOS launch in Q2 of next year. As noted in today’s release, we also remain on track for IQOS ILUMA PMTA and supplemental MRTPA submissions in Q4 2023. Our approach to the US has not changed. We will look to speed up our topline with IQOS and ZYN, backed by disciplined investment and drawing on both our deep experience in smoke-free products and Swedish Match’s infrastructure and knowledge, while still delivering strong bottom-line growth for PMI. Our pilot city launches for BONDS in the Philippines and Colombia keep moving forward well. What we learn in these markets will be folded in as we expand more widely, beginning next year. International growth of nicotine pouches stays a key medium-term opportunity, especially for ZYN as the world’s leading brand; we are currently getting ready for the launch of — re-launch of ZYN in several markets. In e-vapor, our refocused strategy in select markets is advancing with VEEV ONE, our newly designed pod-based system introduced in four markets, and VEEV NOW, our disposable product, in six markets. Now let me turn to our Wellness and Healthcare segment, beginning with its first clinical trial results for our inhalable aspirin product. Although the experimental product was seen to have a rapid onset of effect, which is the key medical advantage sought, there was considerable variability in inhaled dose across subjects. The study was consequently judged unsuccessful, and because of that, improvements to product design are needed. We had intended to submit this product to the FDA before the end of this year. But more time is needed now, which makes the result less predictable. On top of that, the CDMO business has seen development that is slower than we expected, and that includes difficulties tied to cost. As a result, our yearly assessment led us to book a non-cash goodwill impairment, which is described in today's release. These factors will push back when we achieve our 2025 goal of generating more than $1 billion in net revenues from Wellness and Healthcare products, yet they will bring about an equivalent reduction in how much we invest during 2024. Our aims for building and monetizing our product pipeline have not changed. Just as with the early stages of developing IQOS, some headwinds should be anticipated, and the 2021 acquisitions within this segment have given us distinctive and enabling R&D capabilities. We stay dedicated to growing our Wellness & Healthcare business and keep seeing appealing mid and long-term growth potential across many areas, for example inhalable drugs, NRT, and consumer wellness products, among them non-recreational cannabinoids, consistent with applicable regulatory requirements. We also intend to speed up Vectura's growth, and we will look into possible partnerships to strengthen its CDMO business.

Emmanuel Babeau

executive
#5

We intend to cover all of these subjects, among them what we have planned for IQOS in the US plus a comprehensive update regarding our Wellness & Healthcare business, at our Investor Day taking place on the 28th of September in Lausanne, Switzerland. Turning next to sustainability. Tackling the health impact that combustible products have on people by getting adult smokers to move to smoke-free options, for example IQOS and ZYN, is still our single most important priority; this transformation sits at the heart of our strategy, fueling faster growth and returns as time goes on from a business that is more sustainable; beyond that, we stay dedicated to achieving best-in-class advancement across other crucial sustainability areas. Given our vast agricultural and manufacturing supply chain, human rights represent a highly significant duty for our company; last month we published our first report devoted to this subject, laying out our approach to promoting, respecting, and protecting human rights, together with the progress achieved so far in carrying out our human rights commitment. How we perform on human rights forms part of the 19 KPIs within our Sustainability Index, which makes up 30% of executive long-term equity compensation, weighted toward our product transformation. By the close of 2025, we aim to carry out thorough human rights impact assessments across our 10 highest risk markets; these allow us to understand and tackle our impacts more effectively, and our progress has been excellent, with seven finished so far. Another priority for us is tackling climate change, and I'm happy to report that PMI appeared on Forbes' first ever Net Zero Leaders List, coming in seventh overall among all US public companies, ahead of every other consumer products or services company. To wrap up today's presentation, we achieved a very strong first-half in spite of several headwinds, which keeps us on course for a third consecutive year of positive volumes and organic net revenue growth above 7%. The formidable trajectory of our smoke-free business leaves us confident about a strong full year performance, with superb operating income growth. Remarkable momentum keeps building for IQOS and ZYN, the world-leading heat-not-burn and oral nicotine brands, and we have thrilling plans to expand oral nicotine pouches further in the US and internationally, alongside US commercialization of IQOS next year. Crucially, we stay unwavering in our dedication to rewarding our shareholders generously, among other ways through our progressive dividend policy. In summary, our smoke-free transformation keeps producing sustainable growth; we can't wait to share more with you about the next phase of our transformation at our Investor Day on September 28. Thank you so much, and now we're delighted to take your questions.

Pamela Kaufman

analyst
#6

Hello, and good morning. My question concerns the guidance you've provided for the entire year. Your Q2 results came in at least $0.13 above the guidance you had issued yourselves, yet that beat wasn't carried through into the full-year EPS outlook, even after accounting for the larger FX headwind. So what is holding back that Q2 upside from flowing through, and to what degree does this stem from prudence regarding the remainder of the year, as opposed to a more wary view of the second half or increased investment spending? Thank you.

Emmanuel Babeau

executive
#7

Thanks, Pam. If we examine what drove the beat versus our original Q2 expectation, we can probably sort it into three buckets. The first is ZYN performing better than we had expected, and naturally we're factoring that in, since we now see a stronger trajectory for ZYN than we'd initially assumed. Keep in mind that this will only feed into our organic revenue growth in Q4. Still, it certainly helps adjusted EPS growth excluding forex; we also have certain costs that have shifted into H2, and those are, if you like, expenses we'll see in H2, so for the year they aren't a net addition; and then, as we mentioned, there was somewhat better news on financial cost, naturally stemming from our debt. There was also something on tax, and that item is of course more uncertain and harder to forecast for the latter portion of the year; but I think, as always, we're constructing a scenario for the whole year. We've been incorporating clearly what we view as a genuine shift in trajectory and where we have visibility for the second half, along with matters where things have been postponed with favorable news, but naturally we still face considerable uncertainty in H2. Naturally, we need to be somewhat more prudent when we fold those into the scenarios.

Pamela Kaufman

analyst
#8

All right, thank you. Then regarding operating margins, you indicated they'd be nearer the bottom end of your original guidance range — a decline of 50 to 150 basis points for the year. Could you walk through the positives and negatives affecting margin results in the back half?

Emmanuel Babeau

executive
#9

Certainly. Regarding margin, honestly, developments are unfolding as anticipated, I'd say. Following Q1, which didn't catch us off guard, we stated that going forward, an upward shift in the margin path would become visible. We understood inflation would persist through the remaining months, even though during the latter portion of the year, we'll encounter comparisons when inflation had begun to take hold, so that will create some effect; however, we understood several other pressures would begin to ease, and by that I mean supply chain interruptions and, among other items, matters tied to air freight, expenses linked to the ILUMA introduction, and the reality that not all aspects were ideal. Thus, improvement began to appear in Q2 as anticipated, and further improvement will keep appearing throughout the remaining months. Then what we observe influencing Q2 that we anticipate influencing the remaining months are the core favorable forces behind our margin. To begin with, the reality that IQOS expansion is delivering a beneficial effect on our margin; we mentioned this initially, we anticipate a favorable addition to margin movement for the year from the IQOS operation. Keep in mind, we carry a greater gross margin rate on our consumable for IQOS. Therefore, since IQOS keeps expanding, that delivers a favorable effect. There is no — regarding our smokefree operation, an additional force that is favorable for our margin, specifically ZYN, and ZYN within the US, which likewise adds to the margin. You don't observe it in organic reporting thus far, yet it will begin to take effect in Q4 and we anticipate yet another pleasant favorable. And the third component that I believe you clearly notice in Q2 is our capacity to set prices. We witness right now quite plainly on combustible; we face certain pressures that are short-lived originating from Germany and Japan on heat-not-burn, yet we kept our capacity to set prices, which is favorable over the long run. And these are solid components. Naturally, opposite all that we will continue putting money in and ensuring we're maximizing the expansion opportunity, yet that's truly what sits behind the margin movement for the year. Furthermore, on top of that, and I believe we've been mentioning this throughout the quarter, we have the expansion of operations arriving with reduced margin since we are purchasing from (sub-parties), and that represents a distinct margin dynamic. Additionally, the segment we refer to as below V1, which actually involves a decreased excise tax in Indonesia, arrives with a smaller margin. I'd describe it as more of a technical consequence. And as stated, absent that, we would actually have landed in the middle of the range we provided, the negative 50 to 150; and once more, this does not capture the favorable impact from ZYN. So as a recap, I would say developments are unfolding as anticipated, and we are beginning to observe that over the long term there are some basic favorable factors for our margin, which I outlined.

Pamela Kaufman

analyst
#10

Thanks. That helps a lot.

Vivien Azer

analyst
#11

Good morning. I'd like to build on what was said regarding ZYN — it definitely lines up with the extremely strong patterns showing up in Nielsen scanner data, with growth picking up speed and sizable share gains. In the past, you've mentioned the chance to put some additional investment behind that unit — growing the sales team, widening distribution, and boosting velocity. Could you tell us where things stand on that evaluation timeline for ZYN? Thanks.

Emmanuel Babeau

executive
#12

Of course, Vivien. ZYN is — well, we already knew the brand was excellent. What we're witnessing, frankly, exceeds what we first anticipated when Swedish Match was acquired. Awareness of this category is obviously rising; we observe plenty of poly usage. So a portion of users are completely converted, yet there's substantial poly usage; we're talking about individuals finding they can get their nicotine during times when they otherwise couldn't, be it with combustible cigarettes or another inhalable product. That's definitely a factor. I believe there's a strongly favorable lifestyle dimension tied to what's happening in the US, and it's picking up steam. So that, I think, accounts for ZYN's success — it's the emblem of this category — and naturally, today it's capturing the vast majority of growth in the US nicotine pouch segment. That's obviously excellent news, since it means we have a highly dynamic business in the US. To put it plainly, at the group level this is not a minor thing. So you will observe, and you already are observing in the results, what ZYN's US performance is doing. So it's wonderful to have one more engine behind our smoke-free results and, more broadly, the company's financial results. But it also sets things up nicely for IQOS, because beyond what's already working, we'll be able to construct a highly effective commercial engine. You mentioned a bigger sales force — we're in the process of doing that. It's occurring step by step. Naturally, that will benefit ZYN as well as IQOS, and it also strengthens our ability to grow IQOS successfully down the road in the US. There's no combining of forces between ZYN and IQOS; to be clear, at this point we haven't abruptly added several hundred people to the sales force. It's taking place gradually as we build capability for IQOS beginning in Q2 of next year. There's further investment going into our digital capabilities and digital commercial engine. Again, this is only starting. So I don't think it's really driving the growth we're currently seeing from ZYN, but these represent extra strengths and capabilities. Once more, I'd say the incredible teams that IQOS and ZYN could become here in the US down the road have us genuinely thrilled.

Vivien Azer

analyst
#13

That is quite useful. Thanks for that; and for my next question, turning to Wellness and Healthcare, given what we know about some of the difficulties surrounding the clinical trial, I was hoping you might address your goal of bringing down leverage on the balance sheet following the Swedish Match deal, as opposed to the possible requirement for additional M&A when you consider an eventual $1 billion revenue target, recognizing that you have moved that date back. Thank you.

Emmanuel Babeau

executive
#14

Yes, and let me be very clear. What I mean is, our priority is reducing leverage on the balance sheet. Our attention is on realizing the tremendous opportunity present in our smoke-free business. I brought up IQOS and ZYN together. We also definitely aim to expand VEEV. However, I believe the opportunity with IQOS and ZYN is so substantial that this is naturally the main priority at present. And our time and energy are being devoted to getting the most out of that potential, and that will produce deleveraging. So, right now is not the moment for us to consider, shall I say, a structural M&A move into other areas. Our focus is very much on making the most of this tremendous opportunity in our smoke-free business at present.

Vivien Azer

analyst
#15

Thanks.

Gaurav Jain

analyst
#16

Hello, and good morning. I'd like to ask about ZYN in the US. The volumes are arriving well above what I believe consensus expected, or where we stood; and we're also aware that US cigarette volumes have stayed at very weak levels even with easy comparisons. So what's your view on the cannibalization rate of ZYN on US cigarettes right now? And when you project IQOS growth across the coming seven years, if ZYN's cannibalization turns out bigger than assumed, does that then mean the cigarette universe is smaller, which would imply a smaller IQOS opportunity?

Emmanuel Babeau

executive
#17

Gaurav, that's a great question. I think — to start with, as you can imagine, I won't be in a position to provide an exact answer. My belief is there's likely a certain amount of cannibalization, for the reason I referred to. We observe behaviors emerging among people who are probably aware, a combustible user, and they found they can get their nicotine in another way, with certainly a favorable perception regarding when they can do it and the effect on them; now, I can't say whether this is something highly material. So at this point I have no data. I'm certain we will attempt to expand on the ZYN driver on September 28th, but as I stated, I can't share with you any hard data about how it's materializing. Honestly, I don't think this will be truly relevant for IQOS, except perhaps in a very marginal way; but here with IQOS we're talking about smokers who want to enjoy while they still enjoy today's combustible cigarette, but a different product that mimics their pleasure very closely, with clearly personal benefit for their health, and also for their lifestyle; so I don't view the ZYN moment as something that will compete with IQOS in a meaningful way; so I think that isn't something we regard as a risk that would undermine IQOS potential going forward.

Gaurav Jain

analyst
#18

Sure, thank you. My second question concerns the EU ban on heated tobacco flavors. You said there might be some volatility. The California experience after the menthol cigarette ban was pretty bad, with only 70% of menthol smokers apparently staying in the cigarette market. So what's the precedent? Is there any precedent for banning flavored heated tobacco anywhere that supports your view that the impact will be quite minimal?

Emmanuel Babeau

executive
#19

Yes, Gaurav, there is. Let me give two examples. One is in Europe, with the menthol flavor ban in May 2020, which had minimal impact on the combustible business — very, very small. That's one illustration. The other one is actually — since we're talking about growing products — the flavor ban in California that hit ZYN at the end of 2022. There were a few weeks with a blip in volume. Then momentum returned on non-flavored product, in fact with even greater intensity, and the blip was absorbed, and today you see no impact from this ban. So I think here you have two experiences showing this has minimum impact. And again, in California we're comparing with a growing category, which maybe is more appropriate, but referring to combustible in Europe in May 2020, the impact was de minimis.

Gaurav Jain

analyst
#20

All right, absolutely. Many thanks.

Bonnie Herzog

analyst
#21

Fine, thanks. Hello, Emmanuel. I'd like to revisit your outlook, and perhaps ask a brief follow-up. Based on your full-year guidance, it seems a bigger portion rests on Q4. So I'm hoping you can help us grasp your degree of confidence, or visibility, that the business genuinely will pick up that much strength later in the year; and then, I realize it's early, and I'm not asking you to provide guidance for next year, but is there anything worth considering regarding investments you're making this year that could really set you up for even stronger growth next year and beyond?

Emmanuel Babeau

executive
#22

Yes. So, Bonnie, let me try to address H2, and I think you can already observe it in Q2. What I mean is, the momentum behind IQOS exists. We observe it. Our estimate is 1.4 million user growth in Q2. That is a fantastic figure; we observe in-market sales rising. We're aware there is seasonality, yet that doesn't imply the consumer offtake will decline. There are additional ILUMA launches, and some of those occurred at the close of H1, which will also add in the latter portion of the year; so, we observe quite strong momentum there. We observe the efforts we've been making and, as we mentioned, the most intense price increase occurred in Q2, and it will be smaller in H2. And we have been protecting our market share effectively in a market that is resilient; and we might talk about why CC is so resilient, but the reality is that combustible is demonstrating resilience across many geographies; and then there's a ZYN moment, clearly ZYN momentum, and we're not claiming we'll continue growing at 50%, obviously, but clearly we anticipate momentum will carry on very nicely with ZYN and, beginning in Q4, that will also add to organic growth. But regardless, it will fully add to adjusted EPS growth, excluding forex. So, all of that gives us confidence that we are positioned for a very, very good and very strong H2 in terms of performance; now, as we look toward 2024, we think the growth drivers will remain unchanged; so, IQOS, with obviously the Q2 launch in the US, but let's be clear, that will just be the start; so, it won't instantly produce a massive effect; it will be a ramp up, as we described, but there will be numerous countries where ILUMA will be fully delivering. Consider Japan; what occurred in Japan is quite interesting. In fact, we've witnessed something like another acceleration in market share and volume 1 year after ILUMA's launch. So, it's not as though the prior positive effect was occurring in the initial weeks. My take is that building awareness, comprehension, and genuine enthusiasm doesn't happen overnight. After that, ZYN and nicotine pouches come into the picture. To begin with ZYN, we're kicking things off in the US, yet there are also quite a few thrilling introductions beyond the US. So that's shaping up nicely for 2024, though naturally it's too early to discuss ’24, and we'll provide guidance at the appropriate moment.

Bonnie Herzog

analyst
#23

All right, that's clear and useful. Now for my follow-up, I was hoping you could give us additional detail on Japan — your shipment volume looked quite robust during the quarter, and market share rose considerably, so could you walk us through what drove that? Also, I understand BAT will lower prices for glo Hyper beginning in August. So could you describe the competitive landscape as it stands, and perhaps how you think it will shift given those moves, plus whether you'd need to react in any way? Thanks.

Emmanuel Babeau

executive
#24

Certainly, Bonnie. Japan is, naturally, something we're very pleased about. I touched on this — the reality that 12 months after ILUMA's introduction, we're seeing our market share speed up even more. We've now crossed 26%. And like I mentioned, that demonstrates the brand continues gaining ground, bringing in additional users, and setting itself far apart from rivals; and in fact, the portion of category growth we're capturing has kept expanding. Our approach uses two tiers, TEREA and SENTIA, and it's clearly working very well. On one side there's the premium tier, TEREA, featuring plenty of innovation and an excellent flavor experience; on the other, SENTIA sits lower when it comes to positioning. Yet by offering these two, let's call them tiers, we've been able to connect with the widest conceivable set of ILUMA consumers, and that's plainly delivering strong results. In Japan we're once again seeing freight pick up gradually; this was anticipated. A year ago, shipments ran below what consumers actually used; this year that's obviously not the case — things are returning to how they normally work. All of that was fully planned. And indeed we observe competitors attempting to put up a fight. This category continues drawing lots of interest and taking share. They're battling to keep expanding while ILUMA is plainly performing strongly. Thus far, they think their path ahead involves offering a less expensive consumable. That decision is theirs, naturally. I won't offer any opinion on it. Even so, it's evident that in spite of this, we've still been able to increase our share. Still, it's encouraging to note that the entire industry is showing a visibly rising dedication to this category in Japan.

Bonnie Herzog

analyst
#25

Okay. Thanks once more.

Matt Smith

analyst
#26

Hello, and thanks for fielding my question. I'd like to inquire about how quickly ILUMA is being introduced across 50 markets, compared with the 23 markets where it can be bought right now. Should we anticipate that happening more or less uniformly through the back half? And might you address the launch or the broadening, plus how it will affect your operating margin during the back half, and your gross margin too?

Emmanuel Babeau

executive
#27

Indeed, Matt. So, things will happen gradually — for me it's tricky, I mean, launches of ILUMA will occur in various countries during Q3 and Q4. Telling you whether it will be even is hard, since I'd likely need to base that on how large each market is, but it will be spread out reasonably well. To be clear, two third of the IQOS volume already gets exposure to, or gains from, ILUMA being there. So this isn't a small thing, yet a substantial portion is already complete; and as we mentioned, when ILUMA started, we hadn't fully optimized the product or the productivity. That doesn't mean everything gets finished by year-end, but we do anticipate definitely witnessing faster productivity and less weight during the latter portion of the year, which will favorably affect margin movement, completely consistent with what I described regarding several headwinds that are easing as expected. Still, that's genuinely what to anticipate from ILUMA in the latter portion of the year.

Matt Smith

analyst
#28

Thanks for that. And could I just pose one additional question regarding how combustibles have been doing? They've come in stronger when it comes to volume as well as organic revenue contribution, and you offered a few remarks about the demand backdrop holding up better than you'd anticipated given the higher pricing. Could you discuss what factors are letting consumers withstand elasticity better than you expected? Do you think that will carry on now that you're about to lap certain pricing moves?

Emmanuel Babeau

executive
#29

Look, up to now, I believe we've observed that pricing doesn't imply the consumer disappears. I can't say how things will develop further down the road. What we're seeing worldwide in the combustible market, I'd say, is firstly, a handful of markets where, owing to demographics, combustible consumption is rising. I could definitely name India, likely Egypt, Turkey, likely Vietnam, though it isn't a major market for us, where the combustible business is climbing. The resilience also stems from a certain number of markets where smoke-free products are banned. So naturally, that is to some degree shielding the combustible business. As you're aware, that's plainly not something we're fond of. We consider it a significant error, but it's probably lending some resilience to the category as a whole. So that would be my comparison for combustible.

Matt Smith

analyst
#30

Thanks for that, Emmanuel. I'll relay it.

Owen Bennett

analyst
#31

Good afternoon, Emmanuel. Trust you're doing well. So, regarding the fiercer competition, all three of your big tobacco competitors now seem to be in a stronger position, at least compared to before when it comes to what they offer, and the money they're putting in. I was just curious whether you could say something about IQOS trends in certain heated markets that are more competitive, where all three of your major competitors now are present. So, like (indiscernible) for instance; so, how is IQOS share holding up, or is ILUMA gaining less ground in these markets than in others? Are you noticing people trying other brands and then returning to IQOS? Thank you.

Emmanuel Babeau

executive
#32

Sure, Owen. In fact, you might have noticed that our category share stayed steady in Q2, at roughly 75%. So, that demonstrates that yes, competition has increased, yet the quality of IQOS and particularly ILUMA, but not only ILUMA, the whole IQOS offering, is enabling us, even though we're more premium, to keep our category share, which is very good news. Here, I'm referring to volume. You can imagine when it comes to value, that figure is even greater. Now, let's be clear. From the start, we knew, and I can say we were hoping the entire industry would adopt heat-not-burn as the future category for inhalable nicotine product; and it's wonderful to see growing commitment from every player involved. So, no doubt they'll bring innovation. We ourselves, as you can imagine, will keep innovating too. And we will surely see innovation and perhaps new things arriving down the road. Now, after six, seven, almost eight years since IQOS launched, I think when it comes to franchise, when it comes to impact, when it comes to strength, when it comes to brand power, I think we are truly second to none. And we built a clear gap and differential; and I think that's precisely what we achieved with Marlboro previously, since Marlboro was a superior product and recognized as a brand that was unique. But beyond that, we succeeded in creating a unique brand that was extremely appealing. And I think with IQOS, that's what we're repeating now. So IQOS products are clearly better recognized as such. It's a different customer experience, but the IQOS brand is also iconic, and people view that as part of lifestyle and a product they want to associate themselves with, which is a recipe for long-term success.

Owen Bennett

analyst
#33

Great, thanks very much. I appreciate that.

Jared Dinges

analyst
#34

Hello everyone. You mentioned that sea freight can at last be used to serve Japan as Q2 moves along. Can you verify that TEREA sticks are no longer limited by capacity?

Emmanuel Babeau

executive
#35

Yes. For the market where we've been launching as of today, we can confirm there's no constraint, which explains why we've been able to switch to sea freight. That said, a ramp-up is still underway for the remaining markets without ILUMA today, and naturally that ramp-up goes hand in hand with capacity growth. So this doesn't mean that on the 1st of July we could serve 100% of the entire IQOS market with the I ILUMA consumable, but pressure restriction is gone, the return to sea freight proves it, and we have a plan to support growth in the remaining markets over the coming months.

Jared Dinges

analyst
#36

Understood. Then, as a quick follow-up on that point, you mentioned Europe regarding IQOS and noted an additional unfavorable inventory shift during Q2. Is it reasonable for us to anticipate a turnaround in H2? Since, in reality, across H1, the inventory decline has been rather significant.

Emmanuel Babeau

executive
#37

Yeah, actually, that is — of course. Actually, the situation was that Japan closed 2022 with shipment volumes below consumer offtake; throughout 2023, that trend has been flipping. Europe, though, moved in the opposite direction. Keep in mind, ours was excessively low owing to doubts about product availability and energy provision at the manufacturing location; that was anticipated, yet the recovery has largely occurred in Q1, with a bit still remaining in Q2. And at this point, we anticipate returning to a typical pattern of shipments relative to consumer offtake or in-market sales. Consequently, we look forward to a robust H2, regarding both shipment growth and in-market sales across Europe, returning to usual.

Jared Dinges

analyst
#38

Understood. And let me ask just one more quick thing after that. Regarding Russia, with what came out last week or this week, could you just update us on whether that unit is now completely ringfenced?

Emmanuel Babeau

executive
#39

Well, regarding Russia, there's nothing fresh for us to share; in earlier communications we've described how complicated the circumstances were. Nothing has changed. I won't offer any remarks about the state of a business I have no knowledge of. And at this point there is nothing further for us to say about Russia.

Jared Dinges

analyst
#40

Understood. So regarding availability, Russia isn't providing anything to nearby markets right now, correct?

Emmanuel Babeau

executive
#41

As you'd expect, we're following every rule, restriction, and sanction currently in place, and it goes without saying that we're in complete compliance.

Jared Dinges

analyst
#42

Great, thanks.

James Bushnell

executive
#43

Thanks, everyone — that brings today's call to a close. We appreciate you being with us. Should anything else come to mind, feel free to reach out to the Investor Relations team. Enjoy the rest of your day.

Emmanuel Babeau

executive
#44

Talk to you soon. Thank you. Bye.

Operator

operator
#45

That wraps up the program for today. Thanks for joining us. Feel free to leave the call whenever you like, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.